In vivo inhibition of PC-3 human androgen-independent prostate cancer by a targeted cytotoxic bombesin analogue, AN-215 (Q73141867)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11058885 AND SRC:MED&resulttype=core&format=json

1 November 2019

title

In vivo inhibition of PC-3 human androgen-independent prostate cancer by a targeted cytotoxic bombesin analogue, AN-215 (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11058885 AND SRC:MED&resulttype=core&format=json

1 November 2019

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11058885 AND SRC:MED&resulttype=core&format=json

1 November 2019

author name string

A Plonowski

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11058885 AND SRC:MED&resulttype=core&format=json

1 November 2019

A Nagy

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11058885 AND SRC:MED&resulttype=core&format=json

1 November 2019

B Sun

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11058885 AND SRC:MED&resulttype=core&format=json

1 November 2019

K Groot

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11058885 AND SRC:MED&resulttype=core&format=json

1 November 2019

G Halmos

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11058885 AND SRC:MED&resulttype=core&format=json

1 November 2019

language of work or name

English

0 references

publication date

1 November 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11058885 AND SRC:MED&resulttype=core&format=json

International Journal of Cancer

1 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11058885 AND SRC:MED&resulttype=core&format=json

1 November 2019

volume

88

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11058885 AND SRC:MED&resulttype=core&format=json

1 November 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11058885 AND SRC:MED&resulttype=core&format=json

1 November 2019

page(s)

652-657

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11058885 AND SRC:MED&resulttype=core&format=json

High yield conversion of doxorubicin to 2-pyrrolinodoxorubicin, an analog 500-1000 times more potent: structure-activity relationship of daunosamine-modified derivatives of doxorubicin

1 November 2019

cites work

0 references

Yttrium-90-labelled somatostatin-analogue for cancer treatment

0 references

In situ hybridization for gastrin-releasing peptide receptor (GRP receptor) expression in prostatic carcinoma

0 references

Targeted cytotoxic analogue of bombesin/gastrin-releasing peptide inhibits the growth of H-69 human small-cell lung carcinoma in nude mice

0 references

Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors.

0 references

Therapy of neuroendocrine tumors with radiolabeled MIBG and somatostatin analogues

0 references

Interspecies differences in enzymes reacting with organophosphates and their inhibition by paraoxon in vitro.

0 references

Bombesin specifically induces intracellular calcium mobilization via gastrin-releasing peptide receptors in human prostate cancer cells

0 references

Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits the growth of PC-82 human prostate cancer in nude mice

0 references

Effect of somatostatin analog RC-160 and bombesin/gastrin releasing peptide antagonist RC-3095 on growth of PC-3 human prostate-cancer xenografts in nude mice

0 references

Characterization of high-affinity receptors for bombesin/gastrin releasing peptide on the human prostate cancer cell lines PC-3 and DU-145: internalization of receptor bound 125I-(Tyr4) bombesin by tumor cells

0 references

MANAGEMENT OF HORMONE REFRACTORY PROSTATE CANCER: CURRENT STANDARDS AND FUTURE PROSPECTS

0 references

Bombesin stimulates growth of human prostatic cancer cells in vitro

0 references

Reduction in receptors for bombesin and epidermal growth factor in xenografts of human small-cell lung cancer after treatment with bombesin antagonist RC-3095.

0 references

Design, synthesis, and initial evaluation of high-affinity technetium bombesin analogues

0 references

The role of increasing detection in the rising incidence of prostate cancer

0 references

Paclitaxel derivatives for targeted therapy of cancer: toward the development of smart taxanes.

0 references

Stability of cytotoxic luteinizing hormone-releasing hormone conjugate (AN-152) containing doxorubicin 14-O-hemiglutarate in mouse and human serum in vitro: implications for the design of preclinical studies.

0 references

Evaluation of radiolabelled bombesin analogues for receptor-targeted scintigraphy and radiotherapy

0 references

Presence of receptors for bombesin/gastrin-releasing peptide and mRNA for three receptor subtypes in human prostate cancers

0 references

Design, synthesis, and in vitro evaluation of cytotoxic analogs of bombesin-like peptides containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin.

0 references

Identifiers

DOI

10.1002/1097-0215(20001115)88:4<652::AID-IJC21>3.0.CO;2-1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11058885 AND SRC:MED&resulttype=core&format=json

1 November 2019

1 reference